Mediplantex National Pharmaceutical JSC (HNX:MED)

HNX:MED Income Statement

Financials in millions VND. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Jan 1, 2024	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	355,389	443,136	402,741	401,051	343,951	521,391
Revenue Growth (YoY)	-21.25%	10.03%	0.42%	16.60%	-34.03%	-28.43%
Cost of Revenue	274,655	350,574	319,663	321,750	275,877	404,519
Gross Profit	80,735	92,561	83,078	79,301	68,074	116,872
Selling, General & Admin	63,242	70,368	68,897	70,666	59,184	89,651
Operating Expenses	63,242	70,368	68,897	70,666	59,184	89,651
Operating Income	17,493	22,193	14,181	8,634	8,890	27,221
Interest Expense	-927.08	-3,787	-5,394	-5,004	-3,619	-5,815
Interest & Investment Income	1,103	790.11	6,580	5,811	4,790	5,419
Currency Exchange Gain (Loss)	-601.9	-690.35	-45.37	-	-	-
Other Non Operating Income (Expenses)	-1,552	928.43	-212.84	-774.96	-4,533	4,159
EBT Excluding Unusual Items	15,515	19,434	15,109	8,666	5,528	30,984
Gain (Loss) on Sale of Assets	-16.21	-16.21	-185.78	-	-	-
Pretax Income	15,499	19,418	14,923	8,666	5,528	30,984
Income Tax Expense	3,399	4,171	3,179	2,300	1,781	6,562
Net Income	12,100	15,247	11,744	6,366	3,747	24,422
Net Income to Common	12,100	15,247	11,744	6,366	3,747	24,422
Net Income Growth	-25.82%	29.83%	84.49%	69.88%	-84.66%	-31.97%
Shares Outstanding (Basic)	12	12	12	9	6	6
Shares Outstanding (Diluted)	12	12	12	9	6	6
Shares Change (YoY)	-0.03%	-	32.18%	49.59%	-0.05%	-0.01%
EPS (Basic)	975.46	1228.59	946.32	678.00	597.00	3889.00
EPS (Diluted)	975.46	1228.59	946.32	678.00	597.00	3889.00
EPS Growth	-25.80%	29.83%	39.58%	13.57%	-84.65%	-31.96%
Free Cash Flow	69,401	37,674	-84,502	-91,039	7,746	60,527
Free Cash Flow Per Share	5594.96	3035.74	-6809.19	-9696.32	1234.13	9638.35
Dividend Per Share	-	-	900.000	500.000	250.000	-
Dividend Growth	-	-	80.00%	100.00%	-	-
Gross Margin	22.72%	20.89%	20.63%	19.77%	19.79%	22.41%
Operating Margin	4.92%	5.01%	3.52%	2.15%	2.58%	5.22%
Profit Margin	3.40%	3.44%	2.92%	1.59%	1.09%	4.68%
Free Cash Flow Margin	19.53%	8.50%	-20.98%	-22.70%	2.25%	11.61%
EBITDA	22,548	30,109	22,625	18,654	18,426	37,241
EBITDA Margin	6.35%	6.79%	5.62%	4.65%	5.36%	7.14%
D&A For EBITDA	5,055	7,916	8,444	10,020	9,536	10,020
EBIT	17,493	22,193	14,181	8,634	8,890	27,221
EBIT Margin	4.92%	5.01%	3.52%	2.15%	2.58%	5.22%
Effective Tax Rate	21.93%	21.48%	21.30%	26.55%	32.22%	21.18%
Revenue as Reported	355,389	443,136	402,741	401,051	343,951	521,391

Source: S&P Global Market Intelligence. Standard template. Financial Sources.